This study is based on a retrospective review of 51 patients with endometrial carcinoma from Jul. 1976 through Jan. 1993 who were admitted to the Dept. of Obstetrics and Gynecology, Yonsei University College of Medicine. All cases were clinically
stage
and 37 cases were retrospectively restaged using FIGO surgical staging. The FIGO clinical stage distribution for this study was as follows : 37(72.5%) Stage I, 8(15.7%)Stage II, 6(11.8%) Stage III. Surgical staging of 37 cases revealed 25 (67.6%)
Stage
I, 5 (13.5%)Stage II, 6(16.2%)Stage III, 1(2.7%)Stage IV patients. Surgery upstaged 10.7% of clinical stage I. In clinical stage II, 20% were upstaged. In clinical stage III, 25% were upstaged. No down-staging occurred in all stages. Twenty on
surgically staged patients received no adjuvant therapy. The remaining 16 patients had adjuvant treatment which consisted of radiotherapy (62.5%), chemotherapy (25%), combined modality treatment (12.5%). Five-year survival by clinical staging was
as
follows: 69.3: for Stage I, 52.5% for Stage II, 29.2% for Stage III. Five-year survival by surgical staging was as follows: 95% for Stage I, 45% for Stage II, 19.05% for Stage III. Poor histologic grade and myometrial invasion appear to be
significant
prognostic factor and surgical staging is the strongest predictor of survival. In summary, this study demonstrates that surgical staging is indicated to accurately determine the initial extent of disease in endometrial carcinoma.
|